Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection

Journal of Cystic Fibrosis

Volumn 14, Issue 4, 2015, Pages e1-e2

  Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; HUMAN; LETTER; LUNG FIBROSIS; LUNG FUNCTION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPONTANEOUS MUTATION; TREATMENT FAILURE; COMPLICATION; CYSTIC FIBROSIS; FEMALE; GENETICS; LUNG; MALE; MICROBIOLOGY; MUTATION; PSEUDOMONAS INFECTION;

BACTERIAL DNA;

CYSTIC FIBROSIS; DNA, BACTERIAL; FEMALE; HUMANS; LUNG; MALE; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84937638247     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.12.009     Document Type: Letter

References (12)

1. Aurbach A., Kerem E., Assous M.V., Picard E., Bar-Meir M. Is infection with hypermutable Pseudomonas aeruginosa clinically significant?. J Cyst Fibros 2015, 14(3):347-352.
2. Oliver A., Canton R., Campo P., Baquero F., Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288(5469):1251-1254.
3. Macià M.D., Blanquer D., Togores B., Sauleda J., Pérez J.L., Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005, 49(8):3382-3386.
4. Ciofu O., Riis B., Pressler T., Poulsen H.E., Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005, 49(6):2276-2282.
5. Henrichfreise B., Wiegand I., Pfister W., Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 2007, 51(11):4062-4070.
6. Waine D.J., Honeybourne D., Smith E.G., Whitehouse J.L., Dowson C.G. Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. J Clin Microbiol 2008, 46(10):3491-3493.
7. Ferroni A., Guillemot D., Moumile K., Bernede C., Le Bourgeois M., Waernessyckle S., et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr Pulmonol 2009, 44(8):820-825.
8. World Health Organization The evolving threat of antimicrobial resistance. Options for action. WHO Press 2012, Word Health Organization, Switzerland.
9. Maciá M.D., Mena A., Borrell N., Pérez J.L., Oliver A. Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. Antimicrob Agents Chemother 2007, 51(12):4531-4532.
10. Mena A., Smith E.E., Burns J.L., Speert D.P., Moskowitz S.M., Perez J.L., et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008, 190(24):7910-7917.
11. Rodríguez-Rojas A., Oliver A., Blázquez J. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis 2012, 205(1):121-127.
12. Hogardt M., Heesemann J. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr Top Microbiol Immunol 2013, 358:91-118.